| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Thyme Care | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $233.75M | Series D | 9/25/2025 | $75.21M | $1B | $7.63 | CVS Health Ventures, Foresite Capital, Andreessen Horowitz, Concord Health Partners, Town Hall Ventures, AlleyCorp, Frist Cressey Ventures, Morgan Health, Humana, Texas Oncology, Memorial Hermann Health System | ||||
 | Butterfly Network | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $370.76M | Series D | 9/27/2018 | $250M | $1.28B | $10.27 | Bill & Melinda Gates Foundation, Fidelity Investments, Fosun Pharma, Jamaie Dinan | ||||
 | Kailera Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $959.96M | Series B | 10/14/2025 | $603.18M | $1.4B | $14.00 | Bain Capital, Adage Capital Management, Canada Pension Plan Investment Board, Invus, Janus Henderson Investors, Perseverance Capital, QIA, Royalty Pharma, Surveyor Capital, T. Rowe Price, Atlas Venture, Bain Capital Life Sciences, RTW Investments, Sirona Capital | ||||
 | Treeline Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.1B | Series A-2 | 9/3/2025 | $200.1M | $1.83B | $8.61 | Access Industries, ARCH Venture Partners, OrbiMed, GV, KKR, T. Rowe Price Associates, Ajax Health, Casdin Capital, Fidelity, Aisling Capital, Rock Springs Capital, Exor | ||||
 | Clarify | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $408.35M | Series D-1 | 4/5/2022 | $165.63M | $1.45B | $9.32 | SoftBank, BlackRock, Memorial Hermann Health System, Insight Partners, Spark Capital, KKR, Aspenwood Ventures, Rivas Capital, Sigmas Group | ||||
 | Incredible Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $97.08M | Series B | 8/17/2022 | $80M | $1.65B | $85.10 | Base10 Partners, Obvious Ventures, Workday, Andre Iguodala, Chano Fernandez, 444 Capital Fund, Andreessen Horowitz, Kaiser Permanante | ||||
 | IntelyCare | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $117.50K | -- | 1 | Not available | -- | -- | $232.77M | Series CR-B | 12/23/2025 | $25.64M | $3.21B | $41.67 | Undisclosed Investors | ||||
 | TrueBinding | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $166.08M | Series D-1 | 3/17/2023 | $46.08M | $1.21B | $5.08 | Wangsu | ||||
 | Adaptive Biotechnologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $561.37M | Series F-1 | 1/4/2018 | $45M | $1.35B | $10.67 | Microsoft | ||||
 | Bellabeat | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $119.26M | Series C | 9/22/2022 | $21.57M | $1.01B | $35.95 | Frontierspace Ventures | ||||
 | Clover Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $676.33M | Series D | 5/10/2017 | $130M | $1.23B | $9.38 | Baillie Gifford, Expanding Capital, First Round Capital, Greenoaks Capital, GV, Palm Drive Capital, Sequoia Capital, Toba Capital, Western Technology Investment | ||||
 | Olive | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $837.59M | Series H | 7/1/2021 | $450.32M | $4B | $14.13 | Vista Equity Partners, Base10 Partners Advancement Initiative | ||||
 | Thirty Madison | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $649.53M | Series 2-M | 3/14/2022 | $72.53M | $1.11B | $11.63 | Undisclosed Investors | ||||
 | Visby Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $412.97M | Series E | 3/1/2022 | $108.62M | $1.16B | $32.24 | Ping An Voyager Partners, Healthcare of Ontario Pension Plan, John Doerr, Cedars Sinai Medical Center, ND Capital, Artiman Ventures, Pitango Venture Capital, Blue Water Life Science Advisors, Nissim Capital | ||||
 | Areteia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $360M | Series A-1 | 2/21/2025 | $180M | $1.13B | $10.00 | Bain Capital Life Sciences, Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, Population Health Partners, Viking Global Investors, Marshall Wace | ||||
 | Intarcia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $961.46M | Series EE | 9/15/2016 | $475.68M | $3.94B | $60.00 | Baillie Gifford, Luxin Venture Capital, Fidelity Investments, RA Capital Management, Foresite Capital Management, The Pritzker Organization, The Baupost Group | ||||
 | Modern Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $170.58M | Series D | 2/11/2021 | $74M | $1.17B | $44.05 | Founders Fund, Lachy Groom | ||||
 | One Medical Group | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $437.68M | Series I | 8/22/2018 | $250M | $1.5B | $12.43 | The Carlyle Group | ||||
 | Reify Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $490.2M | Series D | 4/21/2022 | $230.78M | $4.78B | $11.11 | Altimeter Capital, Coatue Management, Dragoneer Investment Group, ICONIQ Growth, Adams Street, Battery Ventures | ||||
 | EQRx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $813.88M | Series B | 1/11/2021 | $570M | $1.66B | $2.74 | GV, Bain Capital Life Sciences, Andreessen Horowitz, ARCH Venture Partners, Arboretum Ventures, Casdin Capital, Nextech, Section 32 | ||||
 | Immunai | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $295.22M | Series C-1 | 10/27/2021 | $204.34M | $1.15B | $186.65 | Koch Disruptive Technologies, Talos VC, 8VC, Alexanria Venture Investments, Piedmont, ICON | ||||
 | Inscripta | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $459.69M | Series E | 4/5/2021 | $150M | $1.32B | $8.83 | Fidelity, T. Rowe Price | ||||
 | Nutcracker Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $244.06M | Series C | 3/14/2022 | $167.76M | $1.09B | $10.75 | ARCH Venture Partners | ||||
 | Lyell | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.04B | Series C | 3/5/2020 | $493M | $2.5B | $11.49 | ARCH Venture Partners, Foresite Capital, Milky Way Investments | ||||